• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Investigation Report on China Pemetrexed Market, 2009-2018 Product Image

Investigation Report on China Pemetrexed Market, 2009-2018

  • ID: 2769122
  • February 2014
  • Region: Asia, China
  • 40 Pages
  • China Research & Intelligence

FEATURED COMPANIES

  • Eli Lilly and Company
  • Hansoh Pharmaceutical
  • LILLY France
  • MORE

Pemetrexed, originally developed by Eli Lilly and Company, is a multi-targeted antimetabolite antitumor drug. This product is with huge growth potential in the market.

Approved by FDA in February 2004, pemetrexed is to treat unresectable malignant pleural mesothelioma with cisplatin. It is the first drug approved by FDA to treat the disease. In August 2004 pemetrexed was approved as a second-line drug for local or metastatic non-small cell lung cancer.

So far pemetrexed (brand name ""Alimta"") has been approved to more than 60 countries worldwide. The product has been a best seller of Eli Lilly and Company since it was launched, and its sales value keeps increasing year after year. The CAGR of sales value of pemetrexed was 50.6% from 2004 to 2011. The sales value was only USD 140 million in 2004 and reached USD 460 million in 2005. In 2011, it grew rapidly to USD 2.46 billion.

In the field of antitumor drugs in China, antimetabolic drug is one of the most common types among traditional anti-tumor chemotherapy drugs. Market size of pemetrexed in China has increased rapidly in recent years. The CAGR of its sales value exceeded 70% from 2006 to 2013.

Pemetrexed READ MORE >

FEATURED COMPANIES

  • Eli Lilly and Company
  • Hansoh Pharmaceutical
  • LILLY France
  • MORE

1 Relevant Concepts of Pemetrexed
1.1 Indication
1.2 Sales Status on the Global Market

2 Market Overview of Pemetrexed in China, 2009-2013
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Investigation on Sales Value of Pemetrexed in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region

4 Investigation on Market Share of Major Pemetrexed Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Investigation on Market Size of Pemetrexed by Dosage Form in China, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form

6 Reference Price of Pemetrexed Produced by Different Enterprises in China Hospital Market
6.1 Qilu Pharmaceutical Co., Ltd.
6.2 Hansoh Pharmaceutical
6.3 LILLY France
6.4 Dezhou Pharmaceutical Co., Ltd.
6.5 Nanjing Pharmaceutical Factory Co., Ltd.
6.6 Eli Lilly and Company
6.7 Nanjing Yadong Qitian Pharmaceutical Co., Ltd.
6.8 Jiangsu Aosaikang Pharmaceutical Co., Ltd.

7 Prospect of China Pemetrexed Market, 2014-2018
7.1 Forecast on Incidence of Mammary Cancer
7.2 Forecast on Market Size
7.3 Forecast on Competition Pattern

Selected Charts

Chart Pemetrexed Products Approved to Market in China by 2014
Chart Forecast on Market Size of Hospital-use Pemetrexed in China, 2014-2018
Chart Sales Value of Pemetrexed in Global Market, 2009-2013
Chart Sales Value of Pemetrexed in Hospital Market in China, 2009-2013
Chart Sales Value of Pemetrexed by Region in China, 2009-2013
Chart Market Share of Pemetrexed Enterprises by Sales Value in China, 2009-2013
Chart Price of Pemetrexed Produced by Qilu Pharmaceutical Co., Ltd. in China Hospital Market, 2009-2013
Chart Price of Pemetrexed Produced by Hansoh Pharmaceutical in China Hospital Market, 2009-2013
Chart Price of Pemetrexed (Alimta) Produced by LILLY France in China Hospital Market, 2009-2013

- Qilu Pharmaceutical Co., Ltd.
- Hansoh Pharmaceutical
- LILLY France
- Dezhou Pharmaceutical Co., Ltd.
- Nanjing Pharmaceutical Factory Co., Ltd.
- Eli Lilly and Company
- Nanjing Yadong Qitian Pharmaceutical Co., Ltd.
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Note: Product cover images may vary from those shown

ALSO AVAILABLE IN THE FOLLOWING LANGUAGES

RELATED PRODUCTS

Our Clients

Our clients' logos